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ABSTRACT
We have found that two previously reported exonic
mutations in the PINK1 and PARK7 genes affect
pre-mRNA splicing. To develop an algorithm to
predict underestimated splicing consequences of
exonic mutations at the 5’ splice site, we con-
structed and analyzed 31 minigenes carrying exonic
splicing mutations and their derivatives. We also
examined 189249 U2-dependent 5’ splice sites of
the entire human genome and found that a new
variable, the SD-Score, which represents a common
logarithm of the frequency of a specific 5’ splice site,
efficiently predicts the splicing consequences of
these minigenes. We also employed the information
contents (Ri) to improve the prediction accuracy.
We validated our algorithm by analyzing 32 addi-
tional minigenes as well as 179 previously reported
splicing mutations. The SD-Score algorithm pre-
dicted aberrant splicings in 198 of 204 sites
(sensitivity=97.1%) and normal splicings in 36 of
38 sites (specificity=94.7%). Simulation of all pos-
sible exonic mutations at positions  3,  2 and  1o f
the 189249 sites predicts that 37.8, 88.8 and 96.8%
of these mutations would affect pre-mRNA
splicing, respectively. We propose that the
SD-Score algorithm is a practical tool to predict
splicing consequences of mutations affecting the
5’ splice site.
INTRODUCTION
In eukaryotes, splicing of the nuclear mRNA precursor
(pre-mRNA) takes place mostly within the U2-dependent
spliceosome, a complex of ﬁve uridine-rich small nuclear
(sn) ribonucleoproteins (RNPs): U1, U2, U4, U5 and U6
snRNPs and numerous non-snRNP proteins. In the ﬁrst
step of spliceosome formation, U1 snRNP recognizes
the 50 splice site and regulates initiation of pre-mRNA
splicing (1).
The 50 splice site is composed of the last three
nucleotides of an exon (positions  3,  2 and  1) and
the ﬁrst six nucleotides of an intron (positions +1 to +6).
The consensus sequence of the U2-dependent 50 splice sites
is (C/A)AG|GT(A/G)AGT (2), where the vertical line (|)
represents the exon–intron boundary, and the ‘GT’
dinucleotide at the 50 end of an intron is invariable
(Figure 1A) (3). In the latter stage of pre-mRNA splicing,
U1 snRNA dissociates from the 50 splice site, and U6
snRNA subsequently binds to nucleotides at positions
+2, +5 and +6 (Figure 2A) (4–6).
In the course of identiﬁcation of exonic splicing
mutations in genetic forms of Parkinson’s disease, we
found two splicing mutations at the 50 splice site that
compromise binding to U1 snRNA. To clarify how exonic
mutations at the 50 splice site cause aberrant splicing, we
analyzed 31 minigenes in vitro and examined 189249
putative U2-dependent 50 GT splice sites of the entire
human genome in silico. We found that a new variable, the
SD-Score, in combination with the information contents
(Ri), which represents the amount of information in bits
(7,8), can eﬃciently predict the splicing consequences of
exonic mutations at the 50 splice site. We validated our
algorithm with 32 additional minigenes and with 179
previously reported splicing mutations, and found that the
SD-Score algorithm has a sensitivity of 97.1% and a
speciﬁcity of 94.7%. We believe that the SD-Score
algorithm is a practical tool for predicting the splicing
consequences at the 50 splice site of mutations causing
human disease.
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Exon trappingvector
To examine splicing consequences of exonic mutations, we
constructed minigenes in an exon-trapping vector, pSPL3
(a discontinued product of Invitrogen, Carlsbad, CA,
USA), which was kindly provided by Dr Kazunori
Imaizumi, Department of Anatomy, University of
Miyazaki, Miyazaki, Japan. We introduced a cytomega-
lovirus promoter in place of the simian virus 40 promoter
by means of a megaprimer-based, site-directed mutagen-
esis method (9) and also introduced a PacI recognition
sequence at the multiple cloning site. Because the
nonsense-mediated mRNA decay can degrade a speciﬁc
splicing product with a premature termination codon and
cause misinterpretation of splicing assays (10), we
eliminated a premature stop codon and constructed
pSPL3 vectors with three reading frames to insert any
chimeric exons in-frame (Supplementary Figure 1).
Minigene constructs andmutagenesis
We used the polymerase chain reaction (PCR) to amplify
an exon and the ﬂanking introns of 200bp of the genes of
our interest using normal human genomic DNA extracted
Figure 1. (A) The 50 end of U1 snRNA recognizes three nucleotides at exonic positions  3,  2 and  1 and six nucleotides at intronic positions +1
to +6. Note that the consensus sequence, 50-(C/A)AG|GT(A/G)AGT-30, is complementary to U1 snRNA at most positions. (B and C) The ‘two-
point’ analysis reveals that NCp-nucs at exonic positions  3,  2 and  1 are compensated for by Cp-nucs at positions +4, +5 and +6, and that
NCp-nucs at intronic positions +4, +5 and +6 are compensated for by Cp-nucs at positions  3,  2,  1 and +3. For example, when a
complementary C is used at position  3 (68353 sites), the frequency of a complementary T at position +6 is 42.9% (29307 of 68353). In contrast,
when a noncomplementary T is used at position  3 (22667 sites), the frequency of a complementary T at position +6 is increased to 60.2% (13636
of 22667). The concordance ratio is calculated as (60.2–42.9)/42.9=0.403 (arrow). This means that when position  3 is a noncomplementary T, we
observe a complementary T at position +6 40.3% more frequently than when position  3 is a complementary C. A positive concordance ratio at a
speciﬁc position indicates that a Cp-nuc to U1 snRNA is preferentially used to compensate for an NCp-nuc at another position.
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introduced to the 50 and 30 ends, respectively, of the PCR
product. Each amplicon was inserted into one of the three
pSPL3 vectors so that the reading frame of the chimeric
exon was retained.
For the PARK7 and DYSF genes, wild-type pSPL3
constructs yielded a large proportion of exon-skipped
products. We thus ampliﬁed a genomic segment spanning
the mutation-harboring exon, the ﬂanking introns and the
neighboring exons, and then inserted the amplicon into
the pcDNA3.1(+) mammalian expression vector
(Invitrogen). Diﬀerent splicing consequences between
pSPL3 and pcDNA3.1(+) constructs likely represent the
complexity of splicing analysis.
The U1 snRNA gene with its own promoter was kindly
provided by Dr Alan M. Weiner, Department of
Biochemistry, University of Washington, Seattle, WA,
USA. The U6 snRNA gene with the 50 promoter region of
367bp and a 30 end region of 149bp was ampliﬁed using
normal human genomic DNA extracted from HEK293
cells and was inserted into the pGEM-T Easy Vector
(Promega, Madison, WI, USA).
Naturally occurring and artiﬁcial mutations were
introduced into the inserts with the QuikChange Site-
Directed Mutagenesis Kit (Stratagene, La Jolla, CA,
USA). We conﬁrmed by sequencing that there were no
artifacts in any insert.
Transfectionand RNA analysis
HEK293 cells were maintained in the Dulbecco’s mini-
mum essential medium (DMEM; Sigma–Aldrich,
St Louis, MO, USA) with 10% fetal bovine serum (FBS;
Sigma–Aldrich). At  50% conﬂuency ( 5 10
5cells) in
a 6-well plate, 1ml of fresh Opti-MEM I (Invitrogen)
was substituted for DMEM, and 1mg of a minigene
with 3ml of the FuGENE6 Transfection Reagent
(Roche Diagnostics, Indianapolis, IN, USA) were then
added. After 4h, 2ml of DMEM with 10% FBS was
overlaid, and the cells were incubated overnight. The
transfection medium was replaced with 2ml of fresh
DMEM with 10% FBS, and the transfected cells were
incubated for 48h before RNA extraction. When artiﬁcial
U1 or U6 snRNA vector was used, 50ng of a minigene
and 950ng of each snRNA vector were introduced.
Total RNA was extracted using the GenElute
Mammalian Total RNA Kit (Sigma–Aldrich). DNA
was degraded on-column with the DNase I (Qiagen,
Valencia, CA, USA). Twenty percent of the isolated RNA
was used as a template for cDNA synthesis with the
Oligo(dT)
12–18 primer (Invitrogen) and the SuperScript
II Reverse Transcriptase (Invitrogen). Ten percent of the
synthesized cDNA was used as a template for reverse
transcriptase (RT)–PCR ampliﬁcation with primers
SD6 (50-TCTGAGTCACCTGGACAACC-30) and SA2
(50-GTGAACTGCACTGTGACAAGCTGC-30), both of
which were on the pSPL3 vector. For minigenes in
pcDNA3.1(+), gene-speciﬁc primers were employed.
Ampliﬁcation was performed for 30 to 35 cycles of
denaturation at 948C for 20s, annealing at 528C for 20s
and extension at 728C for 45s. We measured the signal
Figure 2. (A) The U6 snRNA base pairs with nucleotides at positions
+2, +5 and +6. (B) RT–PCR analysis of minigene constructs
transfected into HEK293 cells with artiﬁcial U1 or U6 snRNA.
A single Cp-nuc is introduced into U1 or U6 snRNA while retaining
the mismatch at the mutation. Wt, wild-type construct; Mt, mutation
observed in a patient. For example, +6U1 indicates that a nucleotide
on U1 snRNA corresponding to position +6 is substituted to match
the 50 splice site. Circles and squares represent nucleotides that become
complementary to the artiﬁcial U1 and U6 snRNAs, respectively. The
open arrowhead indicates a normally spliced fragment, whereas the
closed arrowhead indicates an exon-skipped fragment. The rightmost
column shows the densitometric ratio of the exon-skipped fragment.
The asterisk indicates a mixture of fragments due to activated 50 splice
sites four and 13 nucleotides downstream of the native 50 splice site at
the 50 exon of pSPL3. The dagger indicates a heteroduplex formed by
normally spliced and exon-skipped products. Uppercase nucleotides are
complementary to U1 snRNA, whereas lowercase nucleotides are not.
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NIH Image 1.63 program. When the ratio of the aberrant
product of the mutant construct was increased by 2.5-fold
compared with that of the wild-type construct, we
considered the mutant construct to have resulted in
aberrant splicing. We tried several diﬀerent thresholds
and found that the threshold of 2.5-fold best represents
the results of our visual inspections (data not shown).
For the PINK1, CHM, BRCA1, DYSF, F8 and DMD
genes, we cloned and sequenced all RT–PCR fragments to
conﬁrm that the expected normal and aberrant splicings
indeed had taken place in these minigenes.
Insilico analysis
We extracted all the nonredundant 50 GT splice sites in the
entire human genome using the CDS tags in the NCBI
RefSeq Database Build 36.2. Each 50 splice site on the
genome is counted once, even if it is used multiple times in
alternatively spliced transcripts. The analysis was
performed with the PrimePower HPC2500/Solaris 9 super-
computer (Fujitsu Ltd., Tokyo, Japan). Using the JMP-
IN Ver. 5.1.2 software (SAS Institute, Cary, NC, USA),
we statistically determined a threshold for each variable
using the default settings.
In humans,  0.1–0.3% of introns are spliced by the
minor U12-dependent spliceosome (2,11,12), and  70%
of the U12-dependent introns have GT-AG terminal
dinucleotides (13). Previous in silico analyses of the
human genome identiﬁed 275 (12), 469 (14) and 487 (13)
GT-AG U12-dependent introns. We thus eliminated 487
U12-dependent 50 GT splice sites from our analysis,
according to the U12 Intron Database (http://genome.
imim.es/cgi-bin/u12db/u12db.cgi). Our training and vali-
dation data sets (see ‘Results’ section) did not include any
of the known U12-dependent splice sites.
RESULTS
Screeningof exonic splicing mutations in genes
causingParkinson’s disease
To identify exonic splicing mutations in genetic forms of
Parkinson’s disease, we analyzed 57 missense, nonsense
and synonymous mutations deposited in the Human Gene
Mutation Database (http://www.hgmd.cf.ac.uk/) (15) in
the SNCA, PARK2, PINK1 and PARK7 genes using
minigenes (Supplementary Table 1). We found that no
mutation aﬀected an exonic splicing enhancer (ESE) or
silencer (ESS). Two mutations at the 50 splice site,
however, resulted in skipping of the mutation-harboring
exon likely by compromising binding to U1 snRNA. One
mutation was E417G in PINK1 (16) and the other
mutation was E64D in PARK7 (17). To understand how
complementary nucleotides (Cp-nucs) to U1 snRNA at
the 50 splice site compensate for noncomplementary
nucleotides (NCp-nucs) at other positions, we introduced
a single Cp-nuc to the mutant PINK1 and PARK7
minigenes while retaining the mutation (Supplementary
Figure 2A and Supplementary Table 2). We employed
these results to develop an algorithm to predict splicing
consequences of mutations at the 50 splice site.
Recapitulation ofaberrant splicingsdue to previously
reported exonic splicing mutations
We next recapitulated aberrant splicings of six previously
reported exonic splicing mutations at position  2 in the
CHM, FAH, HMBS, UROS, BRCA1 and CYP27A1
genes (Supplementary Figure 2B and Supplementary
Table 2). All mutations except for CYP27A1 caused the
mutation-harboring exon to be skipped. The CYP27A1
mutation is exceptional because it introduces a Cp-nuc
rather than disrupting complementarity (18). We similarly
introduced a Cp-nuc to the mutant constructs while
retaining the mutation. These results were also used for
developing a prediction algorithm of splicing mutations.
Site-directed mutagenesis ofasingle nucleotide
of U1snRNA and U6snRNA
Because the 50 splice site is recognized by both U1 and U6
snRNAs at diﬀerent stages of pre-mRNA splicing
(Figures 1A and 2A), we wondered which nucleotide of
the 50 splice site is most important for binding each
snRNA. To this end, we introduced a single Cp-nuc to U1
or U6 snRNA while retaining the mismatch between U1
or U6 snRNA and the mutation.
Among 11 experiments with artiﬁcial U1 snRNAs,
corrections of U1 snRNA corresponding to position +6
in FAH and to +5 in CHM ameliorated aberrant
splicings, while the others were ineﬃcient (Figure 2B).
Among four experiments with artiﬁcial U6 snRNAs, only
a correction corresponding to position +5 in CHM
partially normalized aberrant splicing (Figure 2B).
In contrast to manipulation of the splicing cis-elements,
introduced artiﬁcial snRNAs are competed by endog-
enous snRNAs, and hence their eﬀects tend to be
compromised. In addition, substitution of these nucleo-
tides might have modiﬁed the core secondary structure
of U1 or U6 snRNA and made it nonfunctional.
Nevertheless, it is interesting to note that corrections of
U1 and U6 snRNAs ameliorate aberrant splicings in some
mutants even in the presence of mismatch at the mutation.
To our knowledge, no similar study has been performed in
this scale (19), but the study size was still too small to draw
a deﬁnite conclusion.
In silico analysis ofhuman 5’ splice sites:
the consensussequence
To examine how the human 50 splice sites are organized
and why the identiﬁed exonic mutations resulted in
aberrant splicings, we analyzed the 50 splice sites of the
entire human genome. According to the NCBI RefSeq
Database, the human genome comprises 28714 annotated
genes with 192643 50 splice sites. Of these sites, 189718
(98.5%) sites carry an invariant GT dinucleotide at
positions +1 and +2, whereas 1859 (1.0%) and 311
(0.2%) sites have GC and AT dinucleotides, respectively.
The remaining 755 (0.4%) sites carry other dinucleotides
and likely include erroneous annotations. We excluded
487 U12-dependent 50 GT splice sites (see ‘Materials and
Methods’ section) and extracted nine nucleotide segments
5998 Nucleic Acids Research, 2007, Vol. 35, No. 18spanning positions  3 and +6 from the remaining
189249 50 GT splice sites.
Analysis of nucleotide frequencies at each position
showed that the ‘winner sequence’ comprising the most
frequently used nucleotides was CAG|GTAAGT
(Table 1), which is entirely complementary to U1
snRNA (Figure 1A). The frequency of Cp-nuc was highest
at position  1, followed in descending order by positions
+5, +4,  2, +3, +6 and  3 (excluding positions +1
and +2, which are invariant in our analysis).
In silico analysis of human 5’ splicesites: the‘two-point’
analysis
We next analyzed how an NCp-nuc to U1 snRNA at a
speciﬁc position is compensated for by a Cp-nuc at the
other positions. The ‘two-point’ analysis revealed that
NCp-nucs at positions +4, +5 and +6 are compensated
for by Cp-nucs at positions  3,  2,  1 and +3
(Figure 1C). Conversely, NCp-nucs at positions  3,  2
and  1 are associated with high concordance ratios at
positions +4, +5 and +6 (Figure 1B). These results
suggest that a stretch of Cp-nucs either in an exonic or an
intronic region is essential for proper splicing, which also
conforms to the notion that consecutive base pairings with
U1 snRNA contribute to recognition of the 50 splice site
(20). It is also interesting to note that a Cp-nuc at position
+6 most frequently compensates for an NCp-nucs at
position  3,  2 and  1, although the frequency of a
Cp-nuc at position +6 is only 47.7% in the human
genome.
In our analysis, we assumed that only A at position +3
is a Cp-nuc. When we regarded both A and G as Cp-nucs
at position +3, the concordance ratio at position +3
became always low (Supplementary Figure 3), likely
because A or G is observed at position +3 in 94.1% of
the human 50 splice sites. This implies that the con-
cordance ratio is less informative, when the frequency of a
Cp-nuc is high.
In silico analysis of human 5’ splicesites: theSD-Score
The ‘two-point’ analysis disclosed interdependence
between two nucleotides at the 50 splice sites. However,
we could not develop a scoring system using the ‘two-
point’ analysis. We thus sought another quantitative
measure to predict splicing consequences. We expected
that the frequency of a speciﬁc 50 splice site sequence in the
human genome would represent the splicing signal
intensity that we hoped to score. We analyzed the entire
human genome and determined the frequency of each
U2-dependent GT splice site sequence. The common
logarithm of the frequency was calculated to give a new
variable, the SD-Score (Supplementary Table 5). For
example, the SD-Score for CAG|GTGAGG, which was
observed at 2562 sites, is log (2562/189249)= 1.868. The
SD-Score of a splice site sequence that never appears in
the human genome should be log (0/189249)= 1 but is
deﬁned as log (0.25/189249)= 5.879 to simplify calcula-
tions. The correlation coeﬃcients of the SD-Score with the
Ri (7,8) and the consensus value (CV), which represents
the similarity of a splice site sequence to the consensus
splice site sequence (21), are 0.678 and 0.694, respectively,
indicating that the SD-Score is similar to, but distinct
from, the other variables.
Prediction ofsplicing consequences using theSD-Score
algorithm
We next examined whether the SD-Score is indeed an
eﬀective scoring variable. To this end, we plotted the
SD-Scores and the SD-Scores of the 31 constructs of the
PARK7, PINK1, CHM, FAH, HMBS, UROS, BRCA1
and CYP27A1 genes (Supplementary Table 2). The SD-
Score is calculated by subtracting the wild-type SD-Score
from the mutant SD-Score. We found that a 50 splice site
with SD-Score> 0.34 does not aﬀect pre-mRNA
splicing in 13 out of 13 sites, whereas a mutant site with
SD-Score< 0.34 and SD-Score< 2.9 causes aberrant
splicing in 9 out of 10 sites. The 50 splice sites with SD-
Score< 0.34 and SD-Score> 2.9 include a mixed
population of three normal and ﬁve aberrant splicings.
We thus employed the Ri value, which is calculated by
subtracting the wild-type Ri from the mutant Ri, and
found that three out of three sites with Ri> 1.45 are
normally spliced, whereas ﬁve out of ﬁve sites with
Ri< 1.45 are aberrantly spliced. Therefore, these
thresholds eﬃciently predict splicing consequences of our
31 minigene constructs (Figure 3).
Previously unrecognized exonic splicing mutationsat
positions 2and  1
To validate the SD-Score algorithm, we employed
previously unrecognized splicing mutations at positions
Table 1. Nucleotide frequencies (%) at U2-dependent 189 249 human 50 GT splice sites
Position  3  2  1 + 1+ 2+ 3 + 4 + 5 + 6
A 33.4 63.5 10.0 59.5 69.4 8.9 17.9
C 36.1 10.9 2.8 2.9 7.7 5.7 15.0
G 18.5 11.6 80.3 100.0 34.6 11.8 77.6 19.4
T 12.0 14.0 6.8 100.0 3.0 11.1 7.8 47.7
Consensus sequence C/A A G G T A/G A G T
Nucleotides that are complementary to U1 snRNA are underlined. In this study, we calculated the CV (21) with the equation
CV ¼
P6
l¼ 3 ðFðn,lÞ 0:570Þ=5:772, where F(n, l) is a ratio of a nucleotide ‘n’ at position ‘l’. Similarly, we calculated the Ri (7,8) with the equation
Ri ¼
P6
l¼ 3 ð2 þ log2ðFðn,lÞÞÞ. We ignored the error function of Ri, because F(n, l) values are calculated using a large number of observations
(189 249 sites), and hence the contribution of the error function should be negligible.
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mutations from the Human Gene Mutation Database,
and searched for mutations at positions  2 and  1. We
then randomly selected three mutations in the DYSF, F8
and ABCD1 genes (Supplementary Table 2) whose
splicing consequences have not been characterized. The
SD-Score algorithm predicted that all the mutations
would aﬀect pre-mRNA splicings, and minigene analyses
conﬁrmed it (Supplementary Figure 2C and
Supplementary Table 2).
We further introduced a single Cp-nuc to each mutant
minigene while retaining the mutation. We thus con-
structed seven artiﬁcial minigenes, and six of these were
spliced as predicted (Supplementary Figure 2C and
Supplementary Table 2).
Previously unrecognized splicing mutations atposition  3
We next sought exonic splicing mutations at position  3,
which has been reported only in two mutations (22,23)
according to the Human 50 Splice Site Database (http://
www.uni-duesseldorf.de/rna/). In the 2477 exonic muta-
tions described above, we identiﬁed six mutations that
disrupt a complementary C nucleotide at position  3
(Supplementary Table 2). The SD-Score algorithm pre-
dicted that four mutations in the GLA, DMD and PARK2
genes would aﬀect pre-mRNA splicing, whereas two
mutations in the ABCD1 and NPC1 genes would not.
We analyzed six mutant minigenes and found that all,
except the PARK2 mutant, were spliced as predicted
(Supplementary Figures 2D and 5, and Supplementary
Table 2). We conﬁrmed in patient’s lymphocytes that a
C-to-T mutation at position  3i nDMD exon 5 indeed
caused the same aberrant splicing as we observed with the
minigene (data not shown). The aberrant splicing due to a
mutation in DMD exon 5, however, was likely successfully
predicted by the SD-Score algorithm, because additional
mutagenesis at position  4, which did not create a novel
cryptic site, failed to show exon skipping (Supplementary
Figure 5).
We also constructed seven artiﬁcial minigenes, and the
SD-Score algorithm successfully predicted the splicing
consequences of all the minigenes (Supplementary
Figure 2D and Supplementary Table 2).
Splicing mutationsin theliterature database
To further validate the SD-Score algorithm, we employed
other exonic and intronic splicing mutations in the
literature database (Supplementary Tables 3 and 4).
We randomly examined 2, 9, 26, 45, 3, 83 and 11 splicing
mutations at positions  3,  2,  1, +3, +4, +5 and +6,
respectively. Our algorithm correctly predicted aberrant
splicings in 174 of the 179 reported mutations and falsely
predicted normal splicings in ﬁve mutations.
DISCUSSION
Clinical implications of exonic splicing mutations
Although our analysis failed to detect ESE- and ESS-
aﬀecting mutations in genetic forms of Parkinson’s
disease, we identiﬁed two exonic splicing mutations at
the 50 splice site: E417G in PINK1 and E64D in PARK7.
These mutations, as well as six other previously unrecog-
nized exonic splicing mutations in the DYSF, F8, ABCD1,
GLA and DMD genes (Supplementary Table 2), have been
reported as synonymous, missense or nonsense mutations.
Discrimination of splicing mutations from other types of
mutations is essential for understanding human diseases,
because diﬀerent phenotypes and diﬀerent therapeutic
options should be considered for diﬀerent disease mecha-
nisms. For example, splicing abnormalities in the
IKBKAP and SMN2 genes can be normalized with kinetin
(24) and sodium valproate (25), respectively.
PredictionofaberrantsplicingsusingtheSD-Scorealgorithm
To predict aberrant splicings due to mutations at the
50 splice site, we developed the SD-Score algorithm using a
training dataset and tested it using a validation dataset.
Except for the PINK1 and PARK7 genes, we selected
mutations without any bias in both minigenes and
previously reported splicing mutations in the literature
database. Of the 63 minigenes examined in the present
study, six normally spliced and seven aberrantly spliced
minigenes required the use of Ri values for analysis.
In contrast, of the 179 splicing mutations in the literature
database, only four mutations required the Ri values
for analysis. Artiﬁcial minigenes that we constructed
to understand interdependence between Cp-nucs and
NCp-nucs carry two nonnative nucleotides, whereas
naturally occurring mutations carry a single nonnative
nucleotide. The SD-Score alone may not be powerful
enough to predict the splicing consequences of
mutants carrying two or more nonnative nucleotides at
the 50 splice site.
Recognition of an exon, however, is dependent not only
on the 50 splice site sequence, but also on other splicing cis-
elements, including the branch point, the polypyrimidine
tract, the 30 splice site and ESEs/ESSs and intronic
enhancers/silencers. Lack of information about the other
Figure 3. The diagram demonstrates the SD-Score algorithm to predict
aberrant splicings due to mutations at the 50 splice site. The algorithm
is based on a training dataset of 31 minigenes and was validated with
testing data sets of 32 additional minigenes and 179 naturally occurring
splicing mutations (Supplementary Tables 2–4).
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RefSeq annotations make the SD-Score algorithm less
accurate. In addition, our training dataset comprises
exclusively minigenes, and minigenes are not always
spliced in the same way as their endogenous counterparts
(Supplementary Figure 4). Moreover, the SD-Score
algorithm is not trained to predict if any of exon-skipping,
activation of a cryptic site, and intron retention occurs due
to a mutation. The SD-Score algorithm, however, can
eﬃciently predict splicing consequences of our datasets
with a sensitivity of 97.1% and a speciﬁcity of 94.7%
(Table 2).
Comparison with thefree energy, CV and Ri
Roca and colleagues (26) reported that the free energy
between the 50 splice site and U1 snRNA can be used to
predict the 50 splice site strength. The SD-Score can
correctly predict 24 out of the 26 active and inactive
cryptic sites in their series (data not shown). The Pearson’s
correlation coeﬃcient between the SD-Score and the free
energy in their series was 0.792, implying that these two
parameters are likely mutually dependent.
We used our training dataset of 31 minigenes and
validation dataset of 32 additional minigenes in an
attempt to develop similar algorithms for the CV (21)
and the Ri (7,8). We found that either the CV or Ri alone
is not as eﬃcient as the SD-Score algorithm for predicting
splicing mutations (Figure 4). Both the CVs and Ris are
based on the sum of information of each position in a
sequence. On the other hand, the SD-Score represents
information of the entire sequence of the 50 splice site,
which should include mutual interdependence between
multiple positions. The SD-Score, CV and Ri, however,
are mutually complementary, and our algorithm indeed
achieved a high sensitivity and a high speciﬁcity with the
help of Ri values.
We also attempted to create a similar algorithm for the
30 splice site but were unsuccessful, likely because the 30
splice site includes at least three splicing cis-elements, and
because a limited number of splicing mutations have been
identiﬁed at the 30 splice site.
Underestimated exonic splicing mutations
Most exonic splicing mutations aﬀecting the 50 splice site
have been reported at position  1. On the other hand, to
our knowledge, only 2 and 14 exonic splicing mutations
have been reported at position  3 and  2, respectively
(Supplementary Tables 2 and 3). When we introduced
in silico all possible mutations that substitute an NCp-nuc
for a Cp-nuc at positions  3,  2 and  1 into the 189249
50 splice sites in the human genome, the SD-Score
algorithm predicted that 37.8%, 88.8% and 96.8% of
these mutations would aﬀect pre-mRNA splicings, respec-
tively (Table 3). These percentages, as well as those of
Figure 4. Scatter graphs of the SD-Scores (A), the CVs (B) and the Ris
(C) of 63 minigenes and 179 splicing mutations in the literature
database. Thirty-nine normally spliced and 24 aberrantly spliced
minigenes and 37 exonic and 142 intronic splicing mutations are
plotted on each graph. Thresholds for the CVs and Ris were
determined with the JMP-IN statistical software to give the best
discrimination between normal and aberrant splicings. For the SD-
Score, we used 31 minigenes as a training data set and other 32
minigenes as a validation data set. We obtained the similar thresholds
of the SD-Score, even when we included 63 minigenes in our training
data set (data not shown).
Table 2. Sensitivity and speciﬁcity of the SD-Score algorithm
Prediction Aberrantly spliced
a Normally spliced
a
Aberrant splicing
b 198 (24
c/174
d)2 ( 2
c/0
d)
Normal splicing
b 6( 1
c/5
d) 36 (36
c/0
d)
Total 204 (25
c/179
d) 38 (38
c/0
d)
The table shows the
aactual and
bpredicted splicing consequences of
c63
minigenes and
d179 splicing mutations at the 50 splice site in the
literature database. The overall sensitivity of the SD-Score algorithm is
97.1% (198 of 204) and the speciﬁcity is 94.7% (36 of 38). The
speciﬁcity is dependent on only our minigene results, because no report
has been made, in which a mutation at the 50 splice site has no eﬀect on
pre-mRNA splicing.
Nucleic Acids Research, 2007, Vol. 35, No. 18 6001intronic mutations at the 50 splice site, are much higher
than we expected. We hope that the SD-Score algorithm
serves as a practical tool to predict splicing mutations at
the 50 splice site and sheds light on underestimated
aberrant splicings in human diseases.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR online.
Supplementary Table 5 is an Excel program to calculate
the SD-Score algorithm.
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